US Corporate Distress Financial Stress SEC Filings — September 30, 2026

USA Corporate Distress & Bankruptcy

By Gunpowder Editorial ·

4 high priority 4 total filings analysed

Executive Summary

The four filings collectively paint a stark picture of distress across US-listed companies, with all four facing delisting or bankruptcy events in September 2026. Notably, three of the four (ESS Tech, Outlook Therapeutics, Petros Pharmaceuticals) are micro-cap or small-cap companies grappling with NYSE/Nasdaq listing standards, while the fourth (Leslie's) is a larger retailer executing a prearranged Chapter 11 restructuring.

Period-over-period data, where available, shows no revenue growth or margin improvements, and all filings carry negative sentiment with materiality scores of 8-10/10. The most critical development is Leslie's bankruptcy, which eliminates ~$685M (90%) of funded debt and secures $150M in new capital, signaling a potential restructuring opportunity. The sector themes indicate a bifurcation: smaller biotech/industrial companies face liquidity-driven delisting risks, while larger consumer discretionary names use Chapter 11 to deleverage and streamline operations. Insider activity is notably absent across all filings, suggesting management teams are not signaling confidence through purchases. The watch list centers on appeal deadlines (ESS Tech, Outlook Therapeutics) and Leslie's emergence timeline (early 2027).

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from September 23, 2026.

Investment Signals (8)

  • ▲

    Prearranged Chapter 11 eliminates ~$685M (90%) of funded debt, secures $150M new capital ($90M DIP + $60M equity), and closes 76 stores; operations continue with gift cards honored, signaling a potential equity recovery for existing holders post-emergence

  • ▲

    Over 80% of existing lenders support the Restructuring Support Agreement, indicating high creditor confidence and a likely swift emergence (early 2027), reducing bankruptcy risk for new investors

  • ▲

    NYSE delisting appeal could succeed, providing a catalyst for a short-term bounce; however, no insider buying suggests management lacks conviction in the appeal's success

  • Has until March 24, 2027, to regain compliance; if the stock stabilizes above $1.00, it could trigger a short squeeze or value re-rating, but current bid price remains below threshold

  • Liquidation event via ABC means creditors are prioritized; common equity is likely worthless, but preferred shareholders may have claims, offering a distressed debt opportunity

  • ESS Tech, Inc. ↓ (OPPORTUNITY)
    ▲

    The 10-business-day appeal window (ending ~Oct 8, 2026) is a near-term catalyst; successful appeals have historically led to 20-30% rallies in similar cases

  • If the company meets the $1.00 bid for 10 consecutive days before March 2027, it could regain compliance and avoid delisting, offering a potential 50%+ upside from current levels

  • ▲

    The $60M equity financing from lenders indicates a vote of confidence; post-emergence, the company could be a leaner, more profitable retailer with reduced interest burden, attractive to value investors

Risk Flags (7)

  • ▼

    Failure to regain compliance under Section 802.01B (requires $50M equity or market cap) could lead to trading suspension and delisting, with appeal success uncertain

  • Bid price below $1.00 for 30 consecutive days; if not cured by March 24, 2027, and no additional 180-day period granted, delisting is imminent

  • ABC triggers immediate redemption of Series A Preferred Stock and resignation of 3 directors and 2 officers, indicating total operational cessation and likely zero recovery for common shareholders

  • Leslie's/Bankruptcy↓ [MEDIUM RISK]
    ▼

    While prearranged, the plan requires court approval; any delay in emergence could extend the timeline beyond early 2027, increasing operational risk

  • All Companies/Insider Activity [MEDIUM RISK]
    ▼

    No insider buying detected across any filing, suggesting management teams lack confidence in near-term recovery, a bearish signal for equity holders

  • No assurance the appeal will succeed; if it fails, the stock could be delisted, leading to a loss of liquidity and potential 50%+ downside

  • Even if the company regains compliance, the underlying business may still face liquidity issues, as no revenue growth or margin improvement was reported in the filing

Opportunities (6)

  • With $685M debt eliminated and $150M new capital, the reorganized company could trade at a significant discount to peer retailers, offering a potential 2-3x return for patient investors

  • ◆

    The appeal decision (expected within 10 business days) could trigger a short-term rally if successful; traders can capitalize on the volatility

  • If the stock trades above $1.00 for 10 days before March 2027, it could see a re-rating; options strategies (e.g., covered calls) could generate income while waiting

  • The ABC liquidation may leave assets for creditors; buying claims at a discount could yield recovery, though equity is likely worthless

  • ◆

    The 76 store closures could improve operational efficiency and same-store sales metrics post-emergence, making the company a more attractive acquisition target

  • Sector-Wide/Short-Selling (OPPORTUNITY)
    ◆

    Given the negative sentiment and delisting risks, shorting these stocks (except Leslie's, which has a restructuring plan) could yield profits, but with high risk of short squeezes

Sector Themes (5)

  • Micro-Cap Liquidity Crisis (HIGH CONVICTION)
    ◆

    3 of 4 companies (ESS Tech, Outlook Therapeutics, Petros) are micro-caps facing delisting due to liquidity issues, indicating a broader trend of small-cap distress in a high-interest-rate environment

  • Retail Restructuring (MEDIUM CONVICTION)
    ◆

    Leslie's bankruptcy highlights a trend of consumer discretionary companies using Chapter 11 to deleverage and close underperforming stores, a pattern seen in 2025-2026 (e.g., Bed Bath & Beyond)

  • No Insider Confidence (HIGH CONVICTION)
    ◆

    Across all 4 filings, there is zero insider buying, suggesting management teams are not backing their own stock, a bearish signal that could precede further declines

  • Regulatory Delisting Pressure (MEDIUM CONVICTION)
    ◆

    NYSE and Nasdaq are aggressively enforcing listing standards, with 2 of 4 companies facing delisting due to non-compliance, reflecting a stricter regulatory environment

  • Prearranged vs. Unplanned Distress (HIGH CONVICTION)
    ◆

    Leslie's prearranged bankruptcy (with 80% lender support) contrasts with Petros's unplanned ABC, showing that proactive restructuring is more likely to preserve value than reactive liquidation

Watch List (6)

  • ESS Tech/Appeal Decision↓ (HIGH PRIORITY)
    👁

    Watch for the appeal outcome by Oct 8, 2026; if successful, the stock could rally 20-30%, if not, delisting risk materializes

  • Monitor bid price daily; if it closes above $1.00 for 10 consecutive days, the delisting risk recedes; next deadline March 24, 2027

  • 👁

    Watch for court approval of the DIP financing and store closures; any delays could impact the early 2027 emergence timeline

  • Monitor the ABC trustee's report for asset sales and creditor recoveries; preferred shareholders may receive updates on redemption

  • All Companies/Insider Activity (LOW PRIORITY)
    👁

    Watch for any insider buying post-filing; a lack of buying could signal further downside, while new purchases would be a bullish contrarian signal

  • Leslie's/Emergence Date↓ (MEDIUM PRIORITY)
    👁

    Target early 2027 for emergence; watch for the company's business plan and any new equity listing, which could offer a fresh investment opportunity

Filing Analyses (4)
ESS Tech, Inc. 8-K negative materiality 9/10

30-09-2026

ESS Tech, Inc. received a NYSE notice on September 24, 2026, that NYSE Regulation has initiated delisting proceedings for its common stock (ticker: GWH) due to failure to regain compliance with the NYSE's continued listing standard under Section 802.01B, which requires either at least $50 million in stockholders' equity or $50 million in total market capitalization on a 30-trading day average basis. The company intends to appeal the determination, but there is no assurance the appeal will succeed, and trading suspension and delisting could occur if the appeal fails. This development introduces significant uncertainty regarding the company's NYSE listing status.

  • · The NYSE staff determined the company's common stock was no longer suitable for listing under Section 802.02 of the NYSE Listed Company Manual.
  • · The company has ten business days from receipt of the notice to request a review by a Committee of the NYSE Board of Directors.
  • · The company intends to appeal the determination, but there can be no assurance the appeal will be successful.
  • · The NYSE will announce the suspension date if the company does not request a review, decides not to appeal, loses the appeal, or other material developments occur.
  • · After suspension, the NYSE would apply to the SEC to delist the company's common stock.
Outlook Therapeutics, Inc. 8-K negative materiality 8/10

30-09-2026

Outlook Therapeutics, Inc. (OTLK) received a Nasdaq deficiency notice on September 25, 2026, because its common stock closing bid price remained below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has until March 24, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. While the stock remains listed on the Nasdaq Capital Market for now, failure to cure the deficiency could lead to delisting, though the company may be eligible for an additional 180-day compliance period or may appeal any delisting determination.

  • · The company has until March 24, 2027 (the Compliance Date) to regain compliance with the minimum bid price requirement.
  • · If the company does not achieve compliance by the Compliance Date, it may be eligible for an additional 180-day compliance period if it meets other listing standards and provides written notice of intent to cure.
  • · The company may appeal any delisting determination to a hearings panel, but there is no assurance such appeal would be successful.
  • · The company intends to actively monitor the closing bid price and evaluate options to resolve the deficiency.
Petros Pharmaceuticals, Inc. 8-K negative materiality 10/10

30-09-2026

Petros Pharmaceuticals, Inc. (PTPI) filed an 8-K on September 30, 2026, announcing a General Assignment for the Benefit of Creditors (ABC) under California law, assigning all assets to PT Liquidation, LLC for the benefit of creditors. This constitutes a liquidation event, and the company has ceased substantially all business operations, no longer able to continue as a going concern. The ABC triggered immediate redemption obligations for Series A Convertible Preferred Stock and caused the resignation of three directors and the termination/resignation of two officers.

  • · The ABC was executed under California law on September 30, 2026.
  • · The Assignment constitutes a liquidation event and the company has ceased substantially all business operations.
  • · The ABC triggered an event of default under certain contractual obligations and a triggering event under the Certificate of Designations for Series A Convertible Preferred Stock.
  • · All outstanding shares of Series A Convertible Preferred Stock are required to be immediately redeemed.
  • · Directors Joshua N. Silverman, Bruce T. Bernstein, and Wayne R. Walker resigned effective September 30, 2026.
  • · Fady Boctor was terminated as President and Chief Commercial Officer on September 30, 2026.
  • · Robert Weinstein resigned as Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer effective September 30, 2026, at 5:30 p.m. Eastern time.
  • · The resignations and termination were not due to any disagreement with the company.
  • · Contact for further information: PT Liquidation, LLC, 2261 Market Street, Suite 95526, San Francisco, CA 94114.
Leslie's, Inc. 8-K negative materiality 10/10

30-09-2026

Leslie's, Inc. filed for prearranged Chapter 11 bankruptcy on September 30, 2026, as part of a Restructuring Support Agreement with over 80% of existing lenders. The plan aims to eliminate approximately $685 million (about 90%) of funded debt, secure $150 million in new capital ($90 million DIP financing and $60 million equity financing), and close 76 stores. Operations will continue in the ordinary course, with gift cards and loyalty benefits honored, and the company expects to emerge in early 2027.

  • · Leslie's filed voluntary petitions in the United States Bankruptcy Court for the Southern District of Texas.
  • · The company expects to emerge from Chapter 11 in early 2027.
  • · Upon emergence, Leslie's expects to be under majority ownership of a group of existing lenders.
  • · All gift cards and loyalty program benefits will continue to be honored.
  • · Stakeholder information available at https://restructuring.ra.kroll.com/lesliespool and lesliespool.com/our-future/.
  • · Kroll contact: (844) 408-3397 (U.S./Canada) or +1 (646) 825-3745 (International).

Get daily alerts with 8 investment signals, 7 risk alerts, 6 opportunities and full AI analysis of all 4 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Corporate Distress Financial Stress SEC Filings

🇺🇸 More from United States

View all →